Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects

Diabetes Care

Volumn 37, Issue 9, 2014, Pages 2609-2615

  Henry, Robert R ^a,b   Mudaliar, Sunder ^a,b   Ciaraldi, Theodore P ^a,b   Armstrong, Debra A ^a   Burke, Paivi ^a   Pettus, Jeremy ^b   Garhyan, Parag ^c   Choi, Siak Leng ^d   Jacober, Scott J ^c   Knadler, Mary Pat ^c   Lam, Eric Chen Quin ^d   Prince, Melvin J ^c   Bose, Namrata ^b   Porksen, Niels ^c   Sinha, Vikram P ^c   Linnebjerg, Helle ^c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Eli Lilly Singapore Pte Ltd   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN GLARGINE; INSULIN PEGLISPRO; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; INSULIN; LONG ACTING INSULIN;

ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE DISPOSAL RATE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFUSION RATE; LIVER; MALE; NEUROLOGIC DISEASE; NORMAL HUMAN; PERIPHERAL VASCULAR SYSTEM; RANDOMIZED CONTROLLED TRIAL; TISSUE DISTRIBUTION; YOUNG ADULT; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECTS; GLUCOSE CLAMP TECHNIQUE; INTRAVENOUS DRUG ADMINISTRATION;

ADULT; BLOOD GLUCOSE; COHORT STUDIES; CROSS-OVER STUDIES; GLUCOSE CLAMP TECHNIQUE; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN, LONG-ACTING; LIVER; MALE; YOUNG ADULT;

EID: 84906691684     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0210     Document Type: Article

References (33)

1. Henriksen JH, Tronier B, Bülow JB. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. Metabolism 1987;36:463-468
2. Samols E, Ryder JA. Studies on tissue uptake of insulin in man using a differential immunoassay for endogenous and exogenous insulin. J Clin Invest 1961;40:2092-2102
3. Campioni M, Toffolo G, Basu R, Rizza RA, Cobelli C. Minimal model assessment of hepatic insulin extraction during an oral test from standard insulin kinetic parameters. Am J Physiol Endocrinol Metab 2009;297:E941-E948
4. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 2005;54:1649-1656
5. Dimitriadis G, Mitrou P, Lambadiari V, Maratou E, Raptis SA. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract 2011;93(Suppl. 1):S52-S59
6. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol 1983;244: E517-E527
7. Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med 1970;282:182-187
8. Cherrington AD, NealDW, Edgerton DS, et al. Inhalation of insulin in dogs: assessment of insulin levels and comparison to subcutaneous injection. Diabetes 2004;53:877-881
9. Eaton RP, Allen RC, Schade DS. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J Clin Endocrinol Metab 1983;56:1294-1300
10. Eaton RP, Allen RC, Schade DS, Standefer JC. "Normal" insulin secretion: the goal of artificial insulin delivery systems? Diabetes Care 1980;3: 270-273
11. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab 2008;10:811-823
12. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011;13 (Suppl. 1):S5-S14
13. Selam JL, Raccah D, Jean-Didier N, Lozano JL, Waxman K, Charles MA. Randomized comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care 1992;15:53-58
14. Saudek CD, Duckworth WC, Giobbie-Hurder A, et al.; Department of Veterans Affairs Implantable InsulinPump Study Group. Implantable insulin pump vs multiple-dose insulin for noninsulin- dependent diabetes mellitus: a randomized clinical trial. JAMA 1996;276:1322-1327
15. Herring R, Jones RH, Russell-Jones DL. Hepatoselectivity and the evolution of insulin. Diabetes Obes Metab 2014;16:1-8
16. Moore MC, Smith MS, Sinha VP, et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2014;63:494-504
17. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16:344-350
18. Owens RA, Lockwood JF, Dunbar JD, et al. In vitro characterization of novel basal insulin LY2605541: reduced mitogenicity and IGF-IR binding. Abstract presented at the 72nd Scientific Sessions of the American Diabetes Association, 8-12 June 2012, Philadelphia, Pennsylvania
19. Sinha VP, Howey DC, Kwang Wei Soon D, et al. Single-dose pharmacokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 in healthy subjects. Abstract presented at the 72nd Scientific Sessions of the American Diabetes Association, 8-12 June 2012, Philadelphia, Pennsylvania
20. Humalog [package insert]. Indianapolis, IN, Eli Lilly & Co, 2013
21. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 2013;36:522-528
22. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of oncedaily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147
23. World Medical Association Declaration of Helsinki. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000; 284:3043-3045
24. Mudaliar S, Mohideen P, Deutsch R, et al. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care 2002;25:1597-1602
25. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959;82:420-430
26. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 1987; 36:914-924
27. Morrow LA, Hompesch M, Jacober SJ, Choi SL, Qu Y, Sinha VP. LY2605541 (LY) exhibits a flatter glucodynamic profile than insulin glargine (GL) at steady state in subjects with type 1 diabetes (T1D). Abstract presented at the 73rd Scientific Sessions of the American Diabetes Association, 21-25 June 2013, Chicago, Illinois
28. Shojaee-Moradie F, Jackson NC, Boroujerdi M, Brandenburg D, Sönksen PH, Jones RH. Demonstration of a relatively hepatoselective effect of covalent insulin dimers on glucose metabolism in dogs. Diabetologia 1995;38:1007-1013
29. Shojaee-Moradie F, Eckey H, Jackson NC, et al. Novel hepatoselective insulin analogues: studies with covalently linked thyroxyl-insulin complexes. Diabet Med 1998;15:928-936
30. Shojaee-Moradie F, Powrie JK, Sundermann E, et al. Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans. Diabetes Care 2000;23:1124-1129
31. Smeeton F, Shojaee Moradie F, Jones RH, et al. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. Diabetologia 2009;52:2317-2323
32. Sönksen PH, Tompkins CV, Srivastava MC, Nabarro JDW. A comparative study on the metabolism of human insulin and porcine proinsulin in man. Clin Sci Mol Med 1973;45:633-654
33. Glauber HS, Henry RR, Wallace P, et al. The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1987;316:443-449